Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy ; volume:14 ; number:1 ; day:1 ; month:5 ; year:2021 ; pages:1-35 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (1.5.2021), 1-35, 12.2021
- Creator
-
Gong, Ying
Klein Wolterink, Roel G. J.
Wang, Jianxiang
Bos, Gerard M. J.
Germeraad, Wilfred T. V.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01083-5
- URN
-
urn:nbn:de:101:1-2021102222364229814347
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gong, Ying
- Klein Wolterink, Roel G. J.
- Wang, Jianxiang
- Bos, Gerard M. J.
- Germeraad, Wilfred T. V.
- SpringerLink (Online service)
Other Objects (12)
Optimization of chimeric antigen receptor (CAR) therapy
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
Optimizations of anti-tumor efficacy during CD19-specific chimeric antigen receptor (CAR) T/NK-cell manufacturing
Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Chimeric antigen receptor (CAR)-engineered NK-92 cells : an off-the-shelf cellular therapeutic for universal tumor targeting
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Optimization of chimeric antigen receptor (CAR) therapy
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
Optimizations of anti-tumor efficacy during CD19-specific chimeric antigen receptor (CAR) T/NK-cell manufacturing
Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Chimeric antigen receptor (CAR)-engineered NK-92 cells : an off-the-shelf cellular therapeutic for universal tumor targeting
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Optimization of chimeric antigen receptor (CAR) therapy
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
Optimizations of anti-tumor efficacy during CD19-specific chimeric antigen receptor (CAR) T/NK-cell manufacturing
Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Chimeric antigen receptor (CAR)-engineered NK-92 cells : an off-the-shelf cellular therapeutic for universal tumor targeting
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy